Create

Sign in to ReadmeX

or

How we handle your data: Privacy Policy

ReadmeX

Your AI reading companion

What would you like to catch up on?

Pick a briefing, or ask your own question.

Your community and people briefings stay personal to you.

Story

a16z Says AI Could Reshape Pharmaceutical R&D Economics

AI summary

Andreessen Horowitz argues that AI could improve drug-development success rates while reducing development time and cost, potentially making pharmaceutical R&D platforms more valuable. A separate report says Geodesic Intelligence’s NovaAtom-Lite outperformed AlphaFold 3 and IsoDDE on benchmark tests. MIT Technology Review China notes that the proposed benefits still require validation through laboratory experiments and clinical results.

In-depth insight

The reports present AI as a potential foundation for faster and more repeatable drug discovery, while emphasizing that benchmark performance and computer simulations do not establish safer, more effective or commercially successful medicines.

This source provides an excerpt. Continue reading on the original site.

#Andreessen Horowitz#NovaAtom-Lite#Geodesic Intelligence#Isomorphic Labs#AlphaFold 3#IsoDDE#Eli Lilly

Read the original
Group chat

No comments yet. Start the conversation.